Summary:
IMI consultation workshop on advanced therapies

Magda Gunn
29.09.2016 • IMI Stakeholder Forum 2016 • Brussels, Belgium
Objectives of the consultation workshop on advanced therapies

The goal of this workshop is to assess the input collected in previous consultations, and draw conclusions to inform the development of an IMI ATMP portfolio of projects that could be launched from 2017 onwards.
Highlights of the discussion

- ATMP – young, very dynamic and also very complex field
- Efforts dominated by academia and biotech – challenges in translation from POC to ultimately commercialisation
- Industry is interested but not yet very engaged
- Encouraging messages from regulatory and HTA
  - Regulation exist and practical application allows for feasibility based adaptability
  - Existing HTA tools are appropriate but consideration needs to be given to areas of uncertainty
  - Need for adequate payment/reimbursement models
Deliverables

- Collaboration of all the key public and private stakeholders as well as patients
- Education and training for all stakeholders including raising public awareness
- Learn from what has already be done – pool, link & explore data, cohorts
- Abandon the old fashioned approach – instead use PPP whole system approach to define fit for purpose dynamics for ATMP development
- Pilot studies – tech transfer, GMP, manufacturing, product development business models
- Focus on diseases with important unmet medical need